It was found to downregulate YTHDF1 or IMP2, can further regulate the GLS1-glutamine metabolic axis, improve the stability of the m6A-modified GSK3β mRNA, inhibition of Wnt/-catenin/cyclin D1 expression, inhibition of CRC cell proliferation, colony formation, and increase the apoptosis levels in CRC cells, To sensitized cisplatin-resistant CRC cells (126–128). The gene discussed is GLS; the disease is colorectal carcinoma.